Eli Lilly (NYSE: LLY) has signed a research and licensing agreement with private biotech company Stipple Bio to develop cancer therapies against multiple targets. Stipple could receive up to $5.9 billion in research, development and commercialisation milestone payments, plus tiered royalties on product sales if therapies reach the market. The deal combines Lilly’s oncology research with Stipple’s molecular-targeting platform, while any payments beyond the undisclosed upfront amount and equity investment will depend on future development and commercial results.
Lilly secures exclusive worldwide rights
The agreement covers multiple drug targets and treatment approaches. Lilly will hold exclusive worldwide rights to develop and commercialise products arising from the collaboration. Stipple will receive an upfront payment and an equity investment from Lilly; the companies did not disclose the amounts.
Stipple may also earn milestone payments tied to research, product development and commercialisation. If Lilly brings a therapy to market, Stipple will be eligible for royalties that increase in tiers according to sales. The $5.9 billion figure is the maximum potential milestone total, not money already paid or guaranteed revenue.
Pointillist platform targets tumour-cell epitopes
Stipple plans to use its proprietary Pointillist Platform to identify new binding molecules that recognise specific sites, or epitopes, on the surface of tumour cells. Lilly intends to combine those discoveries with its own oncology research capabilities to explore multiple treatment approaches.
One aim is to make therapies more selective for tumours and limit damage to healthy tissue. Toxicity has constrained the clinical use of some cancer drug targets. The companies have not disclosed specific drug candidates, clinical data or development timelines, so the potential benefits remain to be tested in further research.
Stipple Chief Executive Jeff Landau said Lilly’s oncology research and drug-development experience could help advance more precise cancer treatments. He added that the collaboration would allow Stipple to broaden the therapeutic applications of its Pointillist platform while continuing to develop its own pipeline.
Stipple plans Phase 1 trial in 2027
In April, Stipple raised $100 million in an oversubscribed Series A round to support early clinical research on its candidate STP-100 and expand its precision-oncology pipeline using the Pointillist platform. The company plans to begin a Phase 1 trial of STP-100 in early 2027. The candidate is an antibody-drug conjugate for solid tumours, including pancreatic cancer.
Stipple was also named to the 2026 Endpoints 11, an annual list of private biotech companies considered to have development potential. The funding and selection provide context for the company’s research efforts but do not amount to clinical validation of its drug candidates.
Lilly also agrees to acquire Calytrix Bio for up to $1.5 billion
In a separate transaction announced the same day, Lilly agreed to acquire Calytrix Bio Inc. for up to $1.5 billion in cash. The deal includes an initial payment to Calytrix shareholders, with additional payments tied to clinical and regulatory milestones. Calytrix is developing targeted therapies for myeloproliferative neoplasms, blood cancers characterised by excessive production of blood cells.
As of November 17, when the related report was published, Lilly shares were down 1.17% at $1,414.87. Earlier market quotes that day also showed the stock lower. The share-price move coincided with the two research deals, but the available information does not specify the market’s response to either transaction.